金斯瑞生物科技(01548.HK):傳奇生物中期淨虧損大幅收窄 研發開支達2.14億美元
格隆匯8月9日丨金斯瑞生物科技(01548.HK)公吿,公司上市附屬公司傳奇生物科技股份有限公司截至2024年6月30日止六個月的許可收入為103.0百萬美元,而上年同期為15.1百萬美元。許可收入增加87.9百萬美元,主要是由於根據楊森cilta-cel全球開發計劃所達成的里程碑性質及時間確認了60.0百萬美元的收入增加。另外,許可收入增加也是由於根據與諾華製藥股份公司簽訂的全球授權合約相關的基礎活動時間確認了27.9百萬美元的收入,該協議旨在開發、生產和商業化LB2102及其他選擇性靶向DLL3的潛在CAR-T療法。
傳奇生物期間合作收入為171.7百萬美元,而上年同期為94.4百萬美元。增加77.3百萬美元,是由於與楊森協議有關的CARVYKTI銷售收入增加。
傳奇生物期間的研發開支為213.6百萬美元,而上年同期為180.7百萬美元。增加32.9百萬美元,主要是由持續的ciltacel研發活動所推動,包括在比利時進行臨牀生產的啟動成本,以及對我們的實體瘤項目的持續投資。
傳奇生物期間的淨虧損為78.0百萬美元,或每股0.21美元,而上年同期的淨虧損為311.2百萬美元,或每股0.91美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.